SCHEMBL1823375

SCHEMBL1823375

CCc1ccc(CC#N)cc1CC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.39
ENPP2 Q13822 1/20 0.39
CYP2A6 P11509 1/20 0.39
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MMP3 P08254 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
FFAR1 O14842 2/20 0.36
BACE1 P56817 1/20 0.35
KMT2A Q03164 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
MAPT P10636 3/20 0.33
ALDH1A1 P00352 2/20 0.33
NPC1 O15118 2/20 0.33
LMNA P02545 2/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11073978 0.86 CYP2A6 (0.42) DHFRCYP2A6KDM4ETDP1L3MBTL1
SCHEMBL18052640 0.84 ENPP2 (0.37) ENPP2CYP2A6KDM4ETDP1MMP3
SCHEMBL11808398 0.82 CYP2A6 (0.39) ENPP2CYP2A6KDM4ETDP1MMP3
SCHEMBL15173486 0.82 ALDH1A1 (0.53) DHFRENPP2CYP2A6KDM4ETDP1
SCHEMBL17157472 0.82 PTPRC (0.40) ENPP2CYP2A6KDM4ETDP1MMP3
SCHEMBL5256978 0.81 BACE1 (0.40) DHFRCYP2A6L3MBTL1BACE1KMT2A
SCHEMBL1679278 0.80 NPC1 (0.42) NPC1RAB9APKM
SCHEMBL15173367 0.77 ALDH1A1 (0.54) TDP1L3MBTL1KMT2AMAPTALDH1A1
SCHEMBL444673 0.77 TRPA1 (0.48) DHFRCYP2A6KDM4EL3MBTL1BACE1
SCHEMBL12416184 0.75 ENPP2 (0.43) ENPP2KDM4ETDP1MMP3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761509-B1 SUBSTITUTED CYCLOALKYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INT (DE) 2011-05-04 EP disclosed
US-7563806-B2 Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-21 US disclosed
US-7423035-B2 Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-09 US disclosed
US-20080146554-A1 Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-19 US disclosed
EP-1761509-A2 SUBSTITUTED CYCLOALKYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-03-14 EP disclosed
WO-2005111002-A2 SUBSTITUTED CYCLOALKYL DERIVATIVES FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 WO disclosed
US-20050261286-A1 Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 US disclosed
EP-1595873-A1 Substituted cycloalkyl derivatives for the treatment of respiratory diseases Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2005-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146554-A1 Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament CHRM1, CHRM2, CHRM3 DHFR 1092/4885ENPP2 592/4885CYP2A6 380/4885
US-20050261286-A1 Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament CHRM1, CHRM2, CHRM3 DHFR 1092/4885ENPP2 592/4885CYP2A6 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.